Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice
© Rasool et al.; licensee BioMed Central Ltd. 2012
Received: 29 September 2011
Accepted: 17 July 2012
Published: 6 August 2012
It is well established that vaccination of humans and transgenic animals against fibrillar Aβ prevents amyloid accumulation in plaques and preserves cognitive function in transgenic mouse models. However, autoimmune side effects have halted the development of vaccines based on full length human Aβ. Further development of an effective vaccine depends on overcoming these side effects while maintaining an effective immune response.
We have previously reported that the immune response to amyloid oligomers is largely directed against generic epitopes that are common to amyloid oligomers of many different proteins and independent of a specific amino acid sequence. Here we have examined whether we can exploit this generic immune response to develop a vaccine that targets amyloid oligomers using a non-human random sequence amyloid oligomer. In order to study the effect of vaccination against generic oligomer epitopes, a random sequence oligomer (3A) was selected as it forms oligomers that react with the oligomer specific A11 antibody. Oligomer mimics from 3A peptide, Aβ, islet amyloid polypeptide (IAPP), and Aβ fibrils were used to vaccinate Tg2576 mice, which develop a progressive accumulation of plaques and cognitive impairment. Vaccination with the 3A random sequence antigen was just as effective as vaccination with the other antigens in improving cognitive function and reducing total plaque load (Aβ burden) in the Tg2576 mouse brains, but was associated with a much lower incidence of micro hemorrhage than Aβ antigens.
These results shows that the amyloid Aβ sequence is not necessary to produce a protective immune response that specifically targets generic amyloid oligomers. Using a non-human, random sequence antigen may facilitate the development of a vaccine that avoids autoimmune side effects.
Alzheimer's disease (AD) is associated with progressive cognitive decline, neuronal loss and the accumulation of senile plaques and neurofibrillary tangles in affected regions of the brain . The original amyloid cascade hypothesis [2, 3] proposed that the accumulation of amyloid plaques was the principal factor in AD pathogenesis. However recent studies indicate that small soluble Aβ aggregates or oligomers may represent the primary pathogenic entities [4–9]. One of the first tests of the therapeutic value of preventing the accumulation of Aβ or facilitating its clearance came from studies by ELAN, who immunized transgenic mouse models of AD with Aβ42 fibrils (fAβ42) . Immunization with fAβ42 (AN1792) results in a nearly complete absence of Aβ plaque deposits, both in mice that were vaccinated prior to the onset of amyloid deposition and in animals that were vaccinated after amyloid deposition was well underway. However, human clinical trials were halted due to a high incidence of meningioencephalitis that is presumably due to an auto inflammatory reaction to immunization with human Aβ. Overcoming the auto inflammatory side effects while maintaining an effective immune response is a hurdle that must be overcome for the development of a human vaccine for AD .
We have previously shown that vaccination of transgenic mouse models of amyloid deposition with an Aβ oligomer mimic antigen is just as effective in reducing amyloid deposition and preventing cognitive dysfunction as vaccination with human fAβ42 . The immune response to this oligomer mimic antigen results in the production of antibodies that recognize generic epitopes in prefibrillar oligomers independent of the precise amino acid sequence. Indeed, vaccination of rabbits with islet amyloid polypeptide (IAPP) oligomer mimics results in the production of an immune serum that specifically recognizes a variety of prefibrillar amyloid oligomers but not fibrils and is indistinguishable from the serum produced in response to vaccination with Aβ oligomer mimics . This indicates that vaccination with the prefibrillar oligomer (PFO) conformation of other peptides gives rise to antibodies that recognize Aβ PFOs, suggesting that vaccination with a non-human random peptide sequence that also forms PFOs would also give rise to this generic PFO specific immune response. Recently, it was reported that vaccination of Tg mice with a 13 residue random sequence peptide derived from the carboxyl terminus of pABri (polymerized British amyloidosis peptide) related peptide reduces amyloid pathology and preserves cognitive function in APP/PS1 transgenic mice . Here we report that vaccination with a random sequence PFO antigen gives rise to a generic PFO specific immune response that recognizes Aβ oligomers and that vaccination of Tg mice with this antigen is as effective in reducing amyloid deposition and preserving cognitive function. The use a non-human amyloid oligomer as a vaccine may overcome potential problems with auto inflammatory side effects observed with human Aβ.
Identification of a random peptide sequence that forms A11 positive prefibrillar oligomers
Immune response in Tg2576 mice vaccinated with prefibrillar oligomer mimics and fibrillar Aβ
Vaccination with 3A oligomer mimics improves cognitive performance
Immunization with 3A oligomer mimics reduces Aβplaque accumulation in Tg2576 mice
Immunization with 3A oligomer mimics reduces soluble and insoluble levels Aβ40 and Aβ42
Immunization with 3A Oligomer mimics reduces microglial activation
GFAP reactivity is decreased in 3A oligomer mimics vaccinated mice
Microhemorrhage is reduced in 3A oligomermimics and IAPP oligomer vaccinated mice
Microhemorrhage foci observed per section
Anti-Aβ immunotherapy is currently one of the leading strategies for AD therapeutic development with several vaccines in human clinical trial [2, 19]. Numerous pre-clinical studies with mouse models of AD have demonstrated the ability of Aβ vaccination to prevent amyloid deposition in the brain. Thus, active immunization with Aβ [10, 20], as well as passive immunization [15–17, 19–27] resulted in a reduction of the amyloid burden in the brain. Importantly, active immunization prevented cognitive decline [28, 29] and passive immunizations were shown to reverse the memory loss in aged Tg2576 mice . While these and other studies did not report any adverse events in AD transgenic mouse models immunized with fibrillar Aβ42, data from the AN1792 vaccine trial reported meningoencephalitis in 6% of the patients. These adverse reactions to Aβ42-immunotherapy appear not to be due to the humoral antibody response, but rather to the cell-mediated autoimmune response which induced a Th1 type immune response in patients that received the AN1792 vaccine [31–37]. Thus, the goal of this pre-clinical study was to investigate the effectiveness of a non human random peptide (oligomer mimic), that induces a Th2-type humoral immune response specific to oligomeric Aβ peptide, but would not be expected to cause Th1 auto inflammatory side effects because the antigen is non-human.
The data presented here indicate that immunization with non-human 3A amyloid random sequence oligomer produces an efficacious immune response in a murine model of AD that is comparable to that of mice immunized with fibrillar Aβ42 and Aβ40 oligomer mimics. We tested escape latency, number of platform crosses in the Morris water maze test (MWM) (which is related to hippocampus), novel object recognition (which is related to cortex) and inhibitory avoidance (which is related to amygdala). It was found that at 14 months, 3A oligomer mimic vaccinated mice have a significant improvement in cognitive function compared to controls. We examined the effect of immunization on the neuropathology in 14 months old mice, and showed a significant reduction in plaques in both cortex and hippocampal region immunized with 3A peptide. The ELISA data shows that the reduction in insoluble Aβ42 is modest (approximately 40%) and mostly absent for Aβ40 in the fibril vaccinated group, while we observed a more robust (approximately 80%) decrease in plaque burden as determined by 6E10 immunoreactivity by IHC. The explanation for this apparent discrepancy is not clear, but it may be due to the fact that the ELISA measures the amount Aß while the immunohistochemistry measures area of the plaque. This may be a reflection of a change of state of the amyloid in the fibril vaccinated group to a more compact or dense state rather than its removal.
These results are consistent with recent findings that vaccination against a random sequence peptide encoded by read through of a stop codon in the pABri mRNA improves cognition and reduces plaques in APP/PS1 mice . Mice immunized with the ABri random peptide produced antibodies that recognize aggregated Aβ, reduced plaque deposition and improve cognition, similar to the results we report here. However, the immune response to this antigen is broader and includes antibodies that react with neurofibrillary tangles and plaques. Together with our results with the 3A random sequence antigen, these results provide strong support to the concept that targeting generic epitopes associated with Aβ aggregates is therapeutically effective. Small but significant levels of this type of antibodies exist in non-vaccinated humans and the levels of these antibodies are inversely correlated with the incidence of AD . These conformation-specific, sequence-independent antibodies are the major antibodies against Aβ that exist in normal human plasma  and these antibodies may account for the reported effectiveness of IVIg in reducing the incidence of AD in humans . IAPP oligomer and 3A oligomer mimics vaccinated mice showed a relatively low titer as compared to Aβ oligomer and Aβ fibril vaccinated groups, yet retaining their efficacy in preventing cognitive deficits and amyloid deposition. Increasing evidence suggests a role for amyloid oligomers as the toxic species responsible for disease progression and pathogenesis independently of the plaque load . In this view, our results suggest that effective targeting of toxic species rather than the overall extent of immune response elicited may be relevant. The higher titer observed for either Aβ oligomer and Aβ fibril vaccinated groups may therefore reflect the recognition of a broader range of aggregated conformations.
There is increasing evidence that Aβ oligomers and fibrils are conformationally and structurally diverse [40–42], which raises the issue of whether the different conformers are differentially associated with pathogenesis . Because monoclonal antibodies recognize these conformers in a mutually exclusive fashion [44, 45], a single antibody may not be able to target all of the pathologically significant forms of Aβ. The polyclonal response to active immunization is broad, suggesting that it may be more beneficial in its ability to target more different conformers of Aβ than a single monoclonal . A potential advantage of vaccination against conformation dependent epitopes is that the resulting antibodies are specific for aggregated forms of Aβ and do not react with Aβ monomer or APP [13, 40]. This suggests that these antibodies may have a better pharmacological profile than antibodies that recognize APP, which is abundantly expressed or Aβ monomer which is a normal product of APP processing and may have normal roles that should not be interfered with. The lack of reactivity with normal human proteins would also be expected to provide a lower potential for autoimmune complications as well.
We also found that the non-Aβ antigens, 3A and IAPP were associated with a much lower incidence of micro hemorrhage than the Aβ oligomer and Aβ fibril groups. Since the conformation dependent immune response to Aβ oligomer and Aβ fibril antigens are distinct while the immune response to the oligomer mimic antigens is common [13, 40], this suggests that the increased incidence of micro hemorrhage may be due to sequence specific antibodies that are common to the Aß containing antigens. This reduced incidence of micro hemorrhage may also contribute to a superior safety profile of the random sequence oligomer antigen, like 3A.
These results demonstrate that vaccination against generic amyloid oligomer epitopes is capable of attenuating cognitive impairment and producing a protective immune response without increasing the incidence of micro hemorrhage, suggesting that vaccination against a non-human amyloid oligomer epitope may be a safer therapeutic strategy for developing an effective vaccine that circumvents auto inflammatory immune complications.
Materials and methods
Preparation of random peptides
We synthesized a series of 8 random sequence 20mers using a restricted set of 8 amino acids, threonine, tyrosine, serine, histidine, isoleucine, valine, phenylalanine and leucine. The sequences of the 20mers were randomly drawn and checked against the human non-redundant protein sequence data base with BLAST to select for sequences that had the lowest homology with human protein sequences. The sequences were synthesized and tested for the ability to form prefibrillar amyloid oligomers using the A11 prefibrillar oligomer specific polyclonal antibody. One of the sequences (peptide 3A: TYLIHVHIITIYHISIYYIV) formed A11 positive oligomers in a time dependent fashion and was selected for further analysis.
Oligomer mimic antigens
Aβ, IAPP and 3A peptide oligomer molecular mimic antigens were prepared by synthesizing carboxyl-terminal thiol derivatives and coupling them to colloidal gold particles as previously described .
Preparation of Aβ prefibrillar oligomers and fibrils
Aβ40 peptides were lyophilized in 50% acetonitrile/ddH2O. Soluble oligomers were prepared by dissolving 1.0 mg of peptide in 400ul hexafluoroisopropanol (HFIP) for 10–20 min at room temperature. 100 μl of the resulting seedless solution was added to 900 μl milliQ H2O in a siliconized Eppendorf tube. The samples were then stirred at 500 RPM using a Teflon coated micro stir bar for 24–48 h at 22°C. The samples were centrifuged for 15 min. at 14,000 × G and the supernatant fraction (pH 2.8–3.5) was transferred to a new siliconized tube and subjected to a gentle stream of N2 for 5–10 min to evaporate the HFIP. Formation of oligomers were confirmed by atomic force microscopy (AFM), electron microscopy (EM) and size exclusion chromatography (SEC) as described . Fibrils were formed by dissolving Aβ42 in 50% HFIP/ddH2O and stirred with closed caps for 7 days. Solution was stirred again for 2 days using open caps to evaporate the HFIP. Fibrils were sedimented, washed, and resuspended in PBS at 2 mg/ml.
New Zealand white rabbits were immunized with 3A oligomer mimics as previously described and the serum collected after significant titer against Aβ oligomers was detected . Preimmune serum was collected from the same rabbits prior to immunization. We immunized young Tg2576 mice (3 months old)  with one of the following antigens: Aβ oligomer, IAPP oligomer, Aβ fibril, random peptide 3A oligomers or control with colloidal gold in PBS. The mice were equally distributed in each group of eight (4 males and 4 females). The antigens were mixed with incomplete Freund’s adjuvant (1:1,v/v) and immunization was done subcutaneously (100 μg/immunization) every month up to 14 months. For controls a mixture of PBS and colloidal gold was used.
Three common tests for cognitive dysfunctions in AD model mice, the Morris Water Maze (MWM) [47, 48] novel-object recognition [48, 49], and passive inhibitory avoidance tests , were performed according to previous reports with minor modifications.
Morris water maze
Morris water maze is a special memory task related to hippocampus. The apparatus used for all water maze tasks was a circular aluminum tank (1.5 m diameter) painted white and filled with water maintained at 26°C–29°C. The maze was located in a room containing simple visual, extra-maze cues. To reduce stress, mice were placed on the platform in both the hidden and cued versions of the task for 15 sec. prior to the first training trial. Mice were trained to swim to a circular clear Plexiglas platform (14 cm diameter) submerged 1.5 cm beneath the surface of the water and invisible to the mice while swimming. The platform location was selected randomly at 14 months test, but was kept constant for each individual mouse throughout training. On each trial, the mouse was placed into the tank at one of four designated start points in a pseudorandom order. Mice were allowed 60 sec. to find the submerged platform. If a mouse failed to find the platform within 60 sec., it was manually guided to the platform and allowed to remain there for 15 sec. After this, each mouse was placed into a holding cage under a warming lamp for 30 s before beginning the next trial. To ensure that memory differences were not due to lack of task learning, mice were given four trials a day for as many days as were required to train the Tg2576 mice to reach the criterion (<20 sec.). To control for overtraining, probe trials were run for each group, both as soon as they reached group criterion and after all groups had reached criterion. We trained the Tg2576 mice for 8 days at 14 months. Retention of the spatial training was assessed 1.5 hr and again 24 hr after the last training trial. Both probe trials consisted of a 60 s free swim in the pool without the platform. Mice were monitored by a camera mounted in the ceiling directly above the pool to record the 1.5 hr and 24 hr test. The parameters measured during the probe trial included initial latency to cross the platform location, number of platform location crosses, and time spent in the quadrant opposite to the one containing the platform during training.
Novel object recognition
The object recognition task used is based on the spontaneous tendency of rodents to explore a novel object longer than a familiar one. On day 1, the mice were allowed to familiarize themselves with the empty open field for 5 minutes. On day 2, they were subjected to a 5-minute exploration session of two identical, symmetrically placed objects A. Ninety minutes and 24 hours later, the animals were subjected to a 3-minute retention session where they were exposed to one object A and to a novel object B (after 90 minutes) or object C (after 24 hours). The times of exploration were recorded, and an object recognition index (ORI) was calculated, such that ORI = (tn - tf)/(tn + tf), where tf and tn represent times of exploring the familiar and novel objects, respectively.
Passive inhibitory avoidance
Amygdala dependent task was evaluated using the passive inhibitory avoidance task , performed in the Gemini Avoidance System (San Diego Instruments, San Diego, CA). The training trial consisted of placing a mouse in the illuminated compartment of the device and recorded the latent time required for the mouse to enter the dark compartment (baseline latency). Upon entering the dark chamber, the door between the two compartments was closed and the animal was immediately given an electric shock to the feet (0.15 mA, 1 s). During the retention trials (conducted 1.5 h and 24 h after the training trial), the mouse was again placed in the illuminated compartment and the latency to enter the dark compartment was recorded. The retention trial was interrupted if the animal took more than 180 seconds to cross into the dark compartment.
ELISA analysis of anti Aβ antibodies
ELISA assays were performed as previously described . Briefly, 200 ng/100 μl of antigen (Aβ oligomer, IAPP oligomer, 3A oligomer mimic, Aβ fibril and Aβ monomer) was plated on ELISA wells and blocked with BSA. Serum samples were serially diluted to an end point of 1:100,000. The secondary antibody used for detection is peroxidase conjugated AffiniPure Goat Anti-mouse IgG (H + L) (Jackson ImmunoResearch). Titer was determined from the midpoint of the dilution curve (IC50).
Tissue collection and immunohistochemistry
After mice were anesthetized with pentobarbital (150 mg/kg, IP), blood was collected by cardiac puncture, and mice were perfused transcardially with cold phosphate-buffered saline (PBS). Brain tissues were fixed overnight with 4% paraformaldehyde in PBS, pH 7.4 at 4°C and stored in PBS/0.02% sodium azide (NaN3) at 4°C until use. Fixed brain tissues were sectioned (40 μm) with a vibratome. Coronal sections were collected in PBS (containing 0.02% sodium azide) and stored at 4°C prior to staining. To stain for Aβ plaques, sections were immersed in 70% formic acid for 5 min. Endogenous peroxidase in tissue was blocked by treating with 3% H2O2 in PBS for 10 min at room temperature. Nonspecific background staining was blocked by 1 h incubation in 2% BSA, 0.3% Triton X-100 (TX) at room temperature. Tissues were incubated with primary antibodies (6E10, GFAP and CD45) overnight at 4°C, rinsed 3 times with PBS,0.1% TX, followed by biotinylated secondary antibodies (anti-rabbit, anti-mouse and anti-rat), detection with an ABC peroxidase kit, and visualization with a 3,3'-diaminobenzidine (DAB) substrate kit (Vector, Burlingame, CA). CD45 (Serotec, Raleigh, NC; 1:3000) staining was done as described previously . Control experiments with primary or secondary antibody omitted resulted in negative staining.
Coronal brain sections were double-immunostained for astrocytes and Aβ plaques. Sections were permeabilized in 0.1% Triton X-100 for 15 min at RT, blocked in 5% bovine albumin/PBS for 1 hour, and then probed with anti-mouse glial fibrillary acidic protein, GFAP (1:1000, Sigma), rabbit anti-fibril OC (1:4000)  for 24 h at RT. Fluorescent-conjugated secondary antibodies (anti-mouse, anti-rabbit Alexa, 1:400, Invitrogen Molecular Probes) were used for detection. Double immunofluorescent images were captured at a magnification of 10x and anayzed by the z-stack confocal microscopic system using Axio Vision (Zeiss).
Immunostaining was observed under a Zeiss Axiovert-200 inverted microscope (Carl Zeiss, Thornwood, NY) and images were acquired with a Zeiss Axiocam high-resolution digital color camera (1300x1030 pixel) using Axiovision 4.1 or 4.6 software. The same software (Carl Zeiss) was used to analyze the digital images. Percent of immunopositive area (% Field Area) (immunopositive area/total image area × 100) was determined for all the markers studied by averaging images of the cortex, hippocampus and subiculum area from 2–3 sections per animal. Digital images were obtained using the same settings and the segmentation parameters constant within a range per given marker and experiment. The mean value of the% Field Area for each marker in each animal was averaged per genotype group with the number of animals per group indicated in Figure legends.
Enzyme-Linked Immunosorbent Assay (ELISA) for soluble and insoluble Aβ
Soluble and insoluble Aβ fractions were isolated from whole brain homogenates using four step extraction protocol . Frozen hemibrains were sequentially extracted. At each step, sonication in an appropriate buffer was followed by centrifugation at 100,000 x g for 1 hr at 4°C. The supernatant was then removed, and the pellet was sonicated in the next solution used in the sequential extraction process. For four-step extraction, sonication of the frozen brain (150 mg/ml wet weight) began in Tris-buffered saline (TBS) (20 mM Tris and 137 mM NaCl, pH 7.6), which contained protease inhibitors (Protease inhibitor cocktail from Sigma St. Louis USA). The next three sequential extraction steps used 1% Triton X-100 in TBS with protease inhibitors, 2% SDS in water with the same protease inhibitors, and 70% formic acid (FA) in water. Soluble fractions were loaded directly onto ELISA plates, whereas insoluble fractions were diluted 1:20 in a neutralization buffer (1 mol/L Tris base, 0.5 mol/L NaH2PO4) before loading. MaxiSorp immunoplates (Nunc, Rochester, NY) were coated with Mab 20.1 antibody (a kind gift from Dr. David Cribbs University of California Irvine) at a concentration of 25 μg/ml in coating buffer (0.1 M/L Na2CO3, pH 9.6) and blocked with 3% bovine serum albumin. Standard solutions for both Aβ40 and Aβ42 were made in the antigen capture buffer (20 mmol/L NaH2PO4, 2 mmol/EDTA, 0.4 M NaCl, 0.05% 3-[(3- cholamidopropyl) dimethylammonio] propanesulfonate, and 1% bovine serum albumin, pH 7.0) and loaded onto ELISA plates in duplicate. Samples were then loaded (also in duplicate) and incubated overnight at 4°C. Plates were then washed and probed with either horseradish peroxidase conjugated anti-Aβ40(C49) or anti-Aβ42(D32) overnight at 4°C. The chromogen was 3,3_,5,5 tetramethylbenzidine, and the reaction was stopped by 30% phosphoric acid. The plates were read at 450 nm using a plate reader (Molecular Dynamics, Sunnyvale, CA). The readings were then normalized to protein concentrations of the samples.
Micro hemorrhage analysis
Coronal brain sections were stained for hemosiderin as previously described . 3 different sections were counted for each mouse and scored independently by two investigators as stage 1–4. Stage 1 is defined as “1 to 5 grains of iron or small micro vessel involvement”; stage 2 is “multiple grains of iron and micro vessel involvement”; Stage 3 is “several positive micro vessels in 1 area”; and Stage 4 is “large blood vessel involvement”. The data shown are the averages of the two independent countings and are presented as the mean +/− the standard error of the mean.
All statistical analysis were performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA). For comparison between antigen vaccinated groups and control vaccinated group, one-way analysis of variance (ANOVA) followed by Dunnet post-test was performed. Probability values less than 0.05 were accepted as statistically significant.
The authors thank Dr. Vitaly Vasilevko for helpful discussion about micro hemorrhage. Supported by NIH AG33069, a UC Biostar Discovery grant and the Larry L. Hillblom Foundation.
- Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991, 82 (4): 239-259. 10.1007/BF00308809.View ArticleGoogle Scholar
- Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992, 256 (5054): 184-185. 10.1126/science.1566067.View ArticlePubMedGoogle Scholar
- Selkoe DJ: Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem. 1996, 271 (31): 18295-18298.View ArticlePubMedGoogle Scholar
- Golde TE, Dickson D, Hutton M: Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr Alzheimer Res. 2006, 3 (5): 421-430. 10.2174/156720506779025189.View ArticlePubMedGoogle Scholar
- Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al: A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006, 440 (7082): 352-357. 10.1038/nature04533.View ArticlePubMedGoogle Scholar
- Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al: High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000, 20 (11): 4050-4058.PubMedGoogle Scholar
- Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002, 416 (6880): 535-539. 10.1038/416535a.View ArticlePubMedGoogle Scholar
- Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999, 155 (3): 853-862. 10.1016/S0002-9440(10)65184-X.PubMed CentralView ArticlePubMedGoogle Scholar
- Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ: Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans. 2002, 30 (4): 552-557.View ArticlePubMedGoogle Scholar
- Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature. 1999, 400 (6740): 173-177. 10.1038/22124.View ArticlePubMedGoogle Scholar
- Wisniewski T, Konietzko U: Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol. 2008, 7 (9): 805-811. 10.1016/S1474-4422(08)70170-4.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhou J, Fonseca MI, Kayed R, Webster SD, Hernandez I, Yazan O, et al: Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's Disease. J Neuroinflammation. 2005, 2 (1): 28-10.1186/1742-2094-2-28.PubMed CentralView ArticlePubMedGoogle Scholar
- Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al: Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007, 2 (18): 18-PubMed CentralView ArticlePubMedGoogle Scholar
- Goni F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, et al: Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One. 2010, 5 (10): e13391-10.1371/journal.pone.0013391.PubMed CentralView ArticlePubMedGoogle Scholar
- Aloisi F: Immune function of microglia. Glia. 2001, 36 (2): 165-179. 10.1002/glia.1106.View ArticlePubMedGoogle Scholar
- Streit WJ: Microglia and Alzheimer's disease pathogenesis. J Neurosci Res. 2004, 77 (1): 1-8. 10.1002/jnr.20093.View ArticlePubMedGoogle Scholar
- Wilcock DM, Colton CA: Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets. 2009, 8: 50-64. 10.2174/187152709787601858.PubMed CentralView ArticlePubMedGoogle Scholar
- Fisher M, Vasilevko V, Passos GF, Ventura C, Quiring D, Cribbs DH: Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy. Stroke. 2011, 42: 3300-3303. 10.1161/STROKEAHA.111.626655.PubMed CentralView ArticlePubMedGoogle Scholar
- Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297 (5580): 353-356. 10.1126/science.1072994.View ArticlePubMedGoogle Scholar
- Schenk D: Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002, 3 (10): 824-828. 10.1038/nrn938.View ArticlePubMedGoogle Scholar
- Decker MW, Gill TM, McGaugh JL: Concurrent muscarinic and beta-adrenergic blockade in rats impairs place-learning in a water maze and retention of inhibitory avoidance. Brain Res. 1990, 513 (1): 81-85. 10.1016/0006-8993(90)91091-T.View ArticlePubMedGoogle Scholar
- Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, et al: Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1 + APP mouse. Exp Neurol. 2002, 173 (2): 183-195. 10.1006/exnr.2001.7754.View ArticlePubMedGoogle Scholar
- Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C: Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis. 2001, 8 (5): 792-806. 10.1006/nbdi.2001.0431.View ArticlePubMedGoogle Scholar
- Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG: Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001, 21 (2): 372-381.PubMedGoogle Scholar
- Su JH, Cummings BJ, Cotman CW: Plaque biogenesis in brain aging and Alzheimer's disease. II. Progressive transformation and developmental sequence of dystrophic neurites. Acta Neuropathol. 1998, 96 (5): 463-471. 10.1007/s004010050920.View ArticlePubMedGoogle Scholar
- Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000, 6 (8): 916-919. 10.1038/78682.View ArticlePubMedGoogle Scholar
- Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al: Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002, 22 (18): 7873-7878.PubMedGoogle Scholar
- Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000, 408 (6815): 982-985. 10.1038/35050116.View ArticlePubMedGoogle Scholar
- Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. [Comment In: Nature. 2000 Dec 21–28;408(6815):915–6 UI: 21020929]. Nature. 2000, 408 (6815): 979-982. 10.1038/35050110.View ArticlePubMedGoogle Scholar
- Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al: Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002, 22 (15): 6331-6335.PubMedGoogle Scholar
- Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003, 61 (1): 46-54. 10.1212/01.WNL.0000073623.84147.A8.View ArticlePubMedGoogle Scholar
- Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al: Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005, 64 (1): 129-131. 10.1212/01.WNL.0000148590.39911.DF.View ArticlePubMedGoogle Scholar
- Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003, 9 (4): 448-452. 10.1038/nm840.View ArticlePubMedGoogle Scholar
- Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14 (1): 11-20.View ArticlePubMedGoogle Scholar
- Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005, 64 (9): 1553-1562. 10.1212/01.WNL.0000159740.16984.3C.View ArticlePubMedGoogle Scholar
- Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, et al: Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006, 169 (3): 1048-1063. 10.2353/ajpath.2006.060269.PubMed CentralView ArticlePubMedGoogle Scholar
- Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al: Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006, 65 (11): 1040-1048. 10.1097/01.jnen.0000240466.10758.ce.View ArticlePubMedGoogle Scholar
- Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, et al: Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A. 2009, 106 (29): 12145-12150. 10.1073/pnas.0904866106.PubMed CentralView ArticlePubMedGoogle Scholar
- Fillit H, Hess G, Hill J, Bonnet P, Toso C: IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology. 2009, 73 (3): 180-185. 10.1212/WNL.0b013e3181ae7aaf.View ArticlePubMedGoogle Scholar
- Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003, 300 (5618): 486-489. 10.1126/science.1079469.View ArticlePubMedGoogle Scholar
- Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R: Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science. 2005, 307 (5707): 262-265. 10.1126/science.1105850.View ArticlePubMedGoogle Scholar
- Kodali R, Williams AD, Chemuru S, Wetzel R: Abeta(1–40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated. J Mol Biol. 2010, 401 (3): 503-517. 10.1016/j.jmb.2010.06.023.PubMed CentralView ArticlePubMedGoogle Scholar
- Glabe CG: Structural classification of toxic amyloid oligomers. J Biol Chem. 2008, 283 (44): 29639-29643. 10.1074/jbc.R800016200.PubMed CentralView ArticlePubMedGoogle Scholar
- Necula M, Kayed R, Milton S, Glabe CG: Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem. 2007, 282 (14): 10311-10324. 10.1074/jbc.M608207200.View ArticlePubMedGoogle Scholar
- Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, et al: Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Abeta oligomers. Mol Neurodegener. 5: 57-
- Kayed R, Glabe CG: Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol. 2006, 413: 326-344.View ArticlePubMedGoogle Scholar
- Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM: Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005, 45 (5): 675-688. 10.1016/j.neuron.2005.01.040.View ArticlePubMedGoogle Scholar
- Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, et al: A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 2000, 408 (6815): 975-979. 10.1038/35050103.View ArticlePubMedGoogle Scholar
- Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002, 5 (5): 452-457.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.